Proton therapy training offered

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy.

BLOOMINGTON, Indiana-Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy. The college has formed a partnership with ProCure Treatment Centers, Inc. to develop a certificate program that will train and credential students enrolled in the College’s Radiation Therapy program, with courses beginning next fall.

Everything but the protons


Procure’s Training and Development Center, located in Bloomington, celebrated its grand opening on March 27. The 20,000-square-foot center is the first facility in the world dedicated to proton therapy training, ProCure said in a media release. The facility offers before-the-job training that simulates all aspects of proton therapy in a replica of a proton therapy treatment center featuring everything but the actual protons.

Headquartered in Bloomington, ProCure Treatment Centers, Inc. was founded in 2005 by John Cameron, PhD, a particle therapy physics pioneer who was pivotal in the development of the Midwest Proton Therapy Institute in Bloomington. ProCure provides management support and a model for the complete design, construction, operation, and maintenance of proton centers.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.